Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PerVision Trial
NCT06094101Phase 2Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Sep 2023
- Primary completion
- Jun 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of individualized peptide vaccine in Ewing sarcoma, rhabdomyosarcoma (RMS), synovial sarcoma (SS), sponsored by University Hospital Tübingen. Started Sep 2023; status: recruiting.
02
Drugs
individualized peptide vaccine
03
Conditions
Ewing sarcomarhabdomyosarcoma (RMS)synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT06094101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094101.